Titlebook: Hodgkin‘s and Non-Hodgkin‘s Lymphoma; John P. Leonard,Morton Coleman Book 2006 Springer-Verlag US 2006 Tumor.blood.bone.bone marrow.cell.d

gangrene

,Management of Early Stage Hodgkin’s Lymphoma,trials are attempting to reduce toxicity while continuing to achieve excellent results. This chapter will review the evolution of treatment for early stage Hodgkin lymphoma and will describe different the different approaches that have been developed.

acquisition

CHASM

Lymphoma Imaging: Nuclear Medicine,d malignancies warrants better and less harmful screening strategies (.). Hence, the early identification of high-risk and low-risk patients can effectively select subpopulations that would benefit from more intensive chemotherapy protocols and can avoid unwarranted further therapy.

嘮叨

0927-3042 Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to

STAT

,Pathology of B-Cell Non-Hodgkin’s Lymphomas and Multiple Myeloma,atures, and biological behavior. The now widely utilized World Health Organization (WHO) classification scheme incorporates our current knowledge of the clinical and pathological features of B-cell neoplasms, and categorizes them into distinct entities (Table 1)..,. It is now generally accepted that

清澈

Relinquish

The Indolent B-Cell Lymphomas,ily recognized category of indolent lymphoma, representing about one quarter of lymphomas in the Western world..–. The incidence of follicular lymphoma is markedly lower in Asia than in the West, for unclear reasons.. Other well-defined indolent lymphomas (and their approximate percentage incidence)

催眠

Diffuse Large B-Cell NHL,r the past 10 years, routine incorporation of monoclonal antibody therapy in treatment regimens has favorably impacted overall survival in most subgroups of patients with DLBCL. Additionally, there has been remarkable progress in the understanding of the biological heterogeneity of this disease. His

統(tǒng)治人類

Mantle Cell Lymphoma: Current Concept in Biology and Treatment, CD5-positive, CD23-negative follicular mantle B cells with typical t(11; 14)(q13;q32) translocation and cyclin Dl protein over-expression. Four histological subtypes of MCL have been described which include mantle zone, nodular, diffuse, and blastoid forms. MCL commonly occurs in elderly patients w

進(jìn)取心

,T-Cell Non-Hogdkin’s Lymphoma,y of T-cell NHL has been documented ranging from 18.3% of NHL diagnosed in Hong Kong to 1.5% in Vancouver, British Columbia. This may in part be a reflection of increased exposure to pathogenic factors such as human T-cell leukemia virus-1 (HTLV-1) and Epstein Barr virus (EBV) in Asian nations.. T-c